Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 12 clients • 21 examiners • 14 art units • 0 of 22 (0%) have an AI response strategy ready
Grimes & Yvon LLP focuses its practice in the Biotechnology & Pharmaceuticals technology area. The firm has managed 532 career applications, providing a dataset for evaluating their performance in this complex field. Currently, the firm has 16 pending office actions, showing an active presence in ongoing patent negotiations.
The firm's resolved allowance rate is 68.85 percent. This rate is achieved with an average of 3.62 office actions per allowance. This 3.62 average indicates a prosecution process that often requires multiple rounds of responses and amendments to satisfy examiner requirements in the Biotechnology & Pharmaceuticals sector. The 68.85 percent allowance rate across 532 career applications reflects the firm's historical success in securing patent grants for their clients.
The 16 pending office actions represent the firm's current active docket. With 532 career applications, the firm has a foundation of experience. Clients can use the 68.85 percent resolved allowance rate and the 3.62 average office actions per allowance to understand the typical intensity and success rate of the prosecution process with this firm.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (9%) |
| §103 only | 4 (18%) |
| §112 only | 1 (5%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 2 (9%) |
| Multi-statute (no §101) | 12 (55%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 2 | 66.9% | +22.5% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
| YU, HONG | 1 | 30.9% | +5.6% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18622971 | Pharmaceutical Composition and Method for Treating or Preventing Candidiasis | YU, HONG | 22d |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
| 18833550 | METHOD FOR THE PRODUCTION OF A PLANT EXTRACT | BOECKELMAN, JACOB A | — |
| 18657524 | ENHANCED GENE DELIVERY METHODS | MONTANARI, DAVID A | — |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | ABBAS, SYED JARAR | — |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | WANG, CHANG YU | — |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | TCHERKASSKAYA, OLGA V | 30d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
| 18833550 | METHOD FOR THE PRODUCTION OF A PLANT EXTRACT | BOECKELMAN, JACOB A | — |
| 18657524 | ENHANCED GENE DELIVERY METHODS | MONTANARI, DAVID A | — |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | WANG, CHANG YU | — |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | — |
| 18575804 | Method of Administering Anti-HPA-1a Monoclonal Antibody | STOICA, ELLY GERALD | — |
| 18575805 | Administration of Anti-HPA-1a Antibodies | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1634 | 2 |
| 1655 | 1 |
| 1674 | 1 |
| 1614 | 1 |
| 1615 | 1 |
| 1699 | 1 |
| 1628 | 1 |
| 1636 | 1 |
| 1633 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | Oxford Biomedica (Us) LLC | BLUMEL, BENJAMIN P | §102§103§112 | Non-Final OA | — | Pending | Nov 07, 2024 | |
| 18833550 | METHOD FOR THE PRODUCTION OF A PLANT EXTRACT | Vertanical GmbH | BOECKELMAN, JACOB A | 1655 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18657524 | ENHANCED GENE DELIVERY METHODS | Angiocrine Bioscience, Inc. | MONTANARI, DAVID A | §103§112 | Non-Final OA | — | Pending | May 07, 2024 | |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | Memorial Sloan Kettering Cancer Center | ABBAS, SYED JARAR | 1674 | §102§112 | Non-Final OA | — | Pending | May 04, 2024 |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | Janssen Pharmaceutica NV | WANG, CHANG YU | §101§102§112DP | Non-Final OA | — | Pending | Apr 04, 2024 | |
| 18622971 | Pharmaceutical Composition and Method for Treating or Preventing Candidiasis | Fempharma, LLC | YU, HONG | 1614 | §103§112 | Final Rejection | 22d | Pending | Mar 31, 2024 |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | Georgetown University | GOLDBERG, JEANINE ANNE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | Fempharma, LLC | TCHERKASSKAYA, OLGA V | 1615 | §112 | Final Rejection | 30d | Pending | Jan 12, 2024 |
| 18575804 | Method of Administering Anti-HPA-1a Monoclonal Antibody | Rallybio Ipa, LLC | STOICA, ELLY GERALD | §102§103§112 | Non-Final OA | — | Pending | Dec 29, 2023 | |
| 18575805 | Administration of Anti-HPA-1a Antibodies | Rallybio Ipa, LLC | STOICA, ELLY GERALD | §103DP | Non-Final OA | — | Pending | Dec 29, 2023 | |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | Queen Mary University Of London | FAUST, AMBER KATHLEEN | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 | |
| 18290252 | USE OF RAGE INHIBITORS TO TREAT CANCER-RELATED COGNITIVE DECLINE | Georgetown University | JARRELL, NOBLE E | 1699 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Georgetown University | BARSKY, JARED | 1628 | §103 | Final Rejection | 89d overdue | Pending | Apr 22, 2023 |
| 18249248 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | Memorial Sloan Kettering Cancer Center | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 15, 2023 |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | Angiocrine Bioscience, Inc. | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2023 |
| 17924980 | METHOD OF TREATMENT OF CANCER OR TUMOUR | USWM CT,LLC | POPA, ILEANA | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Jan 23, 2023 |
| 18011171 | Administration of CEBP-Beta Antagonist and Methods of Use | Sapience Therapeutics, Inc. | STEELE, AMBER D | 1658 | DP | Non-Final OA | — | Pending | Dec 17, 2022 |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | Oxford Biomedica (Us) LLC | GONZALES, JOSEPHINE MARIA | 1631 | §102§103 | Non-Final OA | 69d | Pending | Dec 15, 2022 |
| 17821884 | ADENO-ASSOCIATED VIRUS FORMULATIONS | Oxford Biomedica (Us) LLC | GILL, RACHEL B | 1671 | §103 | Final Rejection | 29d | Pending | Aug 24, 2022 |
| 17775922 | Production System | Oxford Biomedica (Uk) Limited | PENNINGTON, KATIE LEIGH | 1634 | §103§112DP | Non-Final OA | 30d | Pending | May 11, 2022 |
| 17196631 | METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS | Memorial Sloan Kettering Cancer Center | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 7d | Pending | Mar 09, 2021 |
| 17060993 | Magnetically Stabilized Total Hip Replacement Prosthesis | Fellowship Of Orthopaedic Researchers, Inc. | WOLF, MEGAN YARNALL | 3774 | §103 | Final Rejection | — | Pending | Oct 01, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial